Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chroni

@article{Tsimberidou2003FractionatedCV,
  title={Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chroni},
  author={Apostolia-Maria Tsimberidou and Hagop M Kantarjian and Jorge E. Cortes and Deborah A. Thomas and Stefan H Faderl and Guillermo Garcia-Manero and Srdan Verstovsek and Alessandra Ferrajoli and William G Wierda and Yesid Alvarado and Susan M O'Brien and Maher Albitar and Michael J Keating and Francis J Giles},
  journal={Cancer},
  year={2003},
  volume={97 7},
  pages={1711-20}
}
BACKGROUND Therapy for patients with Richter syndrome (RS) or fludarabine-refractory chronic lymphocytic leukemia (CLL) is unsatisfactory. A Phase II study was conducted to evaluate an alternating combination cytotoxic regimen given with rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) in these patients. METHODS Fludarabine-refractory CLL was defined as failure to respond to most recent prior fludarabine-containing regimen. Patients received up to six cycles of… CONTINUE READING
28 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…